Gary A Piazza

List of Publications by Year in Descending Order

103 papers	3,654 citations	35 h-index	58 g-index
110 ext. papers	4,211 ext. citations	5.1 avg, IF	5.19 L-index

#	Paper	IF	Citations
103	The path to the clinic: a comprehensive review on direct KRAS inhibitors.. *Journal of Experimental and Clinical Cancer Research*, **2022**, 41, 27	12.8	7
102	Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.. *Advances in Cancer Research*, **2022**, 153, 131-168	5.9	0
101	Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer.. *Frontiers in Pharmacology*, **2021**, 12, 736951	5.6	3
100	From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity. *Journal of Medicinal Chemistry*, **2021**, 64, 4462-4477	8.3	1
99	Suppression of Colon Tumorigenesis in Mutant Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic Catenin. *Cancer Prevention Research*, **2021**, 14, 995-1008	3.2	2
98	Novel thiazolidine derivatives as potent selective pro-apoptotic agents. *Bioorganic Chemistry*, **2021**, 114, 105143	5.1	0
97	Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors. *Bioorganic Chemistry*, **2020**, 104, 104322	5.1	3
96	Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors. *Bioorganic Chemistry*, **2020**, 98, 103742	5.1	9
95	Targeting cGMP/PKG signaling for the treatment or prevention of colorectal cancer with novel sulindac derivatives lacking cyclooxygenase inhibitory activity **2020**, 3, 1-6		1
94	PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/Catenin transcription, cancer cell growth, and tumor immunity. *Drug Discovery Today*, **2020**, 25, 1521-1527	8.8	7
93	New Isatin-Indole Conjugates: Synthesis, Characterization, and a Plausible Mechanism of Their in vitro Antiproliferative Activity. *Drug Design, Development and Therapy*, **2020**, 14, 483-495	4.4	7
92	Inhibition of the Lysophosphatidylinositol Transporter ABCC1 Reduces Prostate Cancer Cell Growth and Sensitizes to Chemotherapy. *Cancers*, **2020**, 12,	6.6	5
91	Persistent STAT5 activation reprograms the epigenetic landscape in CD4 T cells to drive polyfunctionality and antitumor immunity. *Science Immunology*, **2020**, 5,	28	13
90	Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS. *MedComm*, **2020**, 1, 121-128	2.8	6
89	Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 312	12.8	10
88	Design and synthesis of 1,2,4-triazolo[1,5-a]pyrimidine derivatives as PDE 4B inhibitors endowed with bronchodilator activity. *Archiv Der Pharmazie*, **2019**, 352, e1900002	4.3	5
87	Antiproliferative activity and possible mechanism of action of certain 5-methoxyindole tethered C-5 functionalized isatins. *Drug Design, Development and Therapy*, **2019**, 13, 3069-3078	4.4	2

86	Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers. *International Journal of Molecular Sciences*, **2019**, 21,	6.3	12
85	Synthesis and biological evaluation of certain hydrazonoindolin-2-one derivatives as new potent anti-proliferative agents. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2018**, 33, 867-878	5.6	24
84	The RAS-Effector Interaction as a Drug Target. *Cancer Research*, **2017**, 77, 221-226	10.1	43
83	New hydrazonoindolin-2-ones: Synthesis, exploration of the possible anti-proliferative mechanism of action and encapsulation into PLGA microspheres. *PLoS ONE*, **2017**, 12, e0181241	3.7	23
82	Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in vitro pharmacological profiling. *Drug Design, Development and Therapy*, **2017**, 11, 2333-2346	4.4	37
81	Effects of an unusual poison identify a lifespan role for Topoisomerase 2 in. *Aging*, **2017**, 9, 68-97	5.6	6
80	Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking □catenin and MAPK signaling. *Oncotarget*, **2017**, 8, 69264-69280	3.3	16
79	The interaction between the Wnt/□catenin signaling cascade and PKG activation in cancer. *Journal of Biomedical Research*, **2017**, 31, 189-196	1.5	15
78	Metabolism and growth inhibitory activity of cranberry derived flavonoids in bladder cancer cells. *Food and Function*, **2016**, 7, 4012-4019	6.1	18
77	Design and Synthesis of Substituted Pyridazinone-1-Acetylhydrazones as Novel Phosphodiesterase 4 Inhibitors. *Archiv Der Pharmazie*, **2016**, 349, 104-11	4.3	6
76	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics. *PLoS ONE*, **2016**, 11, e0163615	3.7	15
75	□catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG. *Oncotarget*, **2016**, 7, 5353-65	3.3	28
74	Inhibition of breast cancer cell motility with a non-cyclooxygenase inhibitory derivative of sulindac by suppressing TGF□/miR-21 signaling. *Oncotarget*, **2016**, 7, 7979-92	3.3	9
73	Mining ZINC Database to Discover Potential Phosphodiesterase 9 Inhibitors Using Structure-Based Drug Design Approach. *Medicinal Chemistry*, **2016**, 12, 472-7	1.8	4
72	Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. *Journal of Biomedical Research*, **2016**, 30, 120-133	1.5	9
71	Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1□ *Cancer Research*, **2016**, 76, 2231-42	10.1	65
70	Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention. *American Journal of Physiology - Renal Physiology*, **2015**, 309, G59-70	5.1	44
69	Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and □catenin-dependent TCF transcriptional activity. *Oncogene*, **2015**, 34, 1499-509	9.2	36

68	Autocrine fibroblast growth factor 18 signaling mediates Wnt-dependent stimulation of CD44-positive human colorectal adenoma cells. *Molecular Carcinogenesis*, **2015**, 54, 789-799	5	16
67	Allyl isothiocyanate induces replication-associated DNA damage response in NSCLC cells and sensitizes to ionizing radiation. *Oncotarget*, **2015**, 6, 5237-52	3.3	29
66	Mechanistic Role of MicroRNA in Cancer Chemoprevention by Nonsteroidal Anti-inflammatory Drugs. *Current Pharmacology Reports*, **2015**, 1, 154-160	5.5	4
65	Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10. *Oncotarget*, **2015**, 6, 27403-15	3.3	27
64	Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors. *Scientia Pharmaceutica*, **2015**, 84, 428-446	4.3	4
63	NSAIDs inhibit tumorigenesis, but how?. *Clinical Cancer Research*, **2014**, 20, 1104-13	12.9	153
62	Novel non-cyclooxygenase inhibitory derivatives of naproxen for colorectal cancer chemoprevention. *Medicinal Chemistry Research*, **2014**, 23, 4177-4188	2.2	13
61	Novel quinazolin-4(3H)-one/Schiff base hybrids as antiproliferative and phosphodiesterase 4 inhibitors: design, synthesis, and docking studies. *Archiv Der Pharmazie*, **2014**, 347, 650-7	4.3	11
60	Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer. *PLoS ONE*, **2014**, 9, e98370	3.7	57
59	The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment. *Cancers*, **2014**, 6, 436-58	6.6	132
58	6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines. *ChemMedChem*, **2013**, 8, 1495-504	3.7	15
57	Quinazoline and tetrahydropyridothieno[2,3-d]pyrimidine derivatives as irreversible EGFR tyrosine kinase inhibitors: influence of the position 4 substituent. *MedChemComm*, **2013**, 4, 1202	5	12
56	Synthesis of some dihydropyrimidine-based compounds bearing pyrazoline moiety and evaluation of their antiproliferative activity. *European Journal of Medicinal Chemistry*, **2013**, 70, 273-9	6.8	28
55	Trisubstituted and tetrasubstituted pyrazolines as a novel class of cell-growth inhibitors in tumor cells with wild type p53. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 7343-56	3.4	3
54	Sulindac sulfide inhibits sarcoendoplasmic reticulum Ca2+ ATPase, induces endoplasmic reticulum stress response, and exerts toxicity in glioma cells: relevant similarities to and important differences from celecoxib. *Journal of Neuroscience Research*, **2013**, 91, 393-406	4.4	17
53	Design of novel β-carboline derivatives with pendant 5-bromothienyl and their evaluation as phosphodiesterase-5 inhibitors. *Archiv Der Pharmazie*, **2013**, 346, 23-33	4.3	12
52	Synthesis and in vitro antiproliferative effect of novel quinoline-based potential anticancer agents. *European Journal of Medicinal Chemistry*, **2013**, 63, 826-32	6.8	49
51	MicroRNA and cancer chemoprevention. *Cancer Prevention Research*, **2013**, 6, 401-9	3.2	31

50	MicroRNAs are involved in the self-renewal and differentiation of cancer stem cells. *Acta Pharmacologica Sinica*, **2013**, 34, 1374-80	8	20
49	An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor B- and hypoxia-inducible factor 1Emediated up-regulation of CXCR4. *Journal of Biological Chemistry*, **2013**, 288, 21197-21207	5.4	122
48	New NSAID targets and derivatives for colorectal cancer chemoprevention. *Recent Results in Cancer Research*, **2013**, 191, 105-20	1.5	21
47	Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/Eatenin signaling. *Molecular Cancer Therapeutics*, **2013**, 12, 1848-59	6.1	83
46	COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs. *Frontiers in Oncology*, **2013**, 3, 181	5.3	74
45	Hypoxia-regulated microRNAs in human cancer. *Acta Pharmacologica Sinica*, **2013**, 34, 336-41	8	111
44	A novel sulindac derivative inhibits lung adenocarcinoma cell growth through suppression of Akt/mTOR signaling and induction of autophagy. *Molecular Cancer Therapeutics*, **2013**, 12, 663-74	6.1	30
43	Sulindac inhibits tumor cell invasion by suppressing NF-B-mediated transcription of microRNAs. *Oncogene*, **2012**, 31, 4979-86	9.2	58
42	Exploring the PDE5 H-pocket by ensemble docking and structure-based design and synthesis of novel Ecarboline derivatives. *European Journal of Medicinal Chemistry*, **2012**, 57, 329-43	6.8	14
41	Aquaporins mediate the chemoresistance of human melanoma cells to arsenite. *Molecular Oncology*, **2012**, 6, 81-7	7.9	33
40	Novel Therapeutics: NSAIDs, Derivatives, and Phosphodiesterases. *Current Colorectal Cancer Reports*, **2012**, 8, 325-330	1	6
39	A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and Ecatenin transcriptional activity. *Cancer Prevention Research*, **2012**, 5, 822-33	3.2	56
38	Honokiol: a novel natural agent for cancer prevention and therapy. *Current Molecular Medicine*, **2012**, 12, 1244-52	2.5	159
37	MiR-181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit. *Cell Death and Differentiation*, **2012**, 19, 378-86	12.7	107
36	CoMFA and CoMSIA studies of 1,2-dihydropyridine derivatives as anticancer agents. *Medicinal Chemistry*, **2012**, 8, 372-83	1.8	5
35	Four-component synthesis of 1,2-dihydropyridine derivatives and their evaluation as anticancer agents. *Medicinal Chemistry*, **2012**, 8, 392-400	1.8	15
34	Synthesis and molecular modeling of novel tetrahydro-Ecarboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties. *Journal of Medicinal Chemistry*, **2011**, 54, 495-509	8.3	39
33	Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/Ecatenin pathway. *PLoS ONE*, **2011**, 6, e29290	3.7	155

32	Design, synthesis and structure-activity relationship of functionalized tetrahydro-β-carboline derivatives as novel PDE5 inhibitors. *Archiv Der Pharmazie*, **2011**, 344, 149-57	4.3	19
31	Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells. *Cancer Prevention Research*, **2011**, 4, 1275-84	3.2	77
30	A high-throughput screen with isogenic PTEN+/+ and PTEN-/- cells identifies CID1340132 as a novel compound that induces apoptosis in PTEN and PIK3CA mutant human cancer cells. *Journal of Biomolecular Screening*, **2011**, 16, 383-93		9
29	Synthesis, Molecular Modeling, and Biological Evaluation of Novel Tetrahydro-β-Carboline Hydantoin and Tetrahydro-β-Carboline Thiohydantoin Derivatives as Phosphodiesterase 5 Inhibitors. *International Journal of Medicinal Chemistry*, **2011**, 2011, 562421	1.7	2
28	NSAIDs: Old Drugs Reveal New Anticancer Targets. *Pharmaceuticals*, **2010**, 3, 1652-1667	5.2	35
27	Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. *Cancer Prevention Research*, **2010**, 3, 1303-13	3.2	62
26	A novel sulindac derivative lacking cyclooxygenase-inhibitory activities suppresses carcinogenesis in the transgenic adenocarcinoma of mouse prostate model. *Cancer Prevention Research*, **2010**, 3, 885-95	3.2	9
25	A novel access to arylated and heteroarylated beta-carboline based PDE5 inhibitors. *Medicinal Chemistry*, **2010**, 6, 374-87	1.8	5
24	A high-throughput screen for chemical inhibitors of exocytic transport in yeast. *ChemBioChem*, **2010**, 11, 1291-301	3.8	5
23	Discovery of colon tumor cell growth inhibitory agents through a combinatorial approach. *European Journal of Medicinal Chemistry*, **2010**, 45, 90-7	6.8	50
22	Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective. *European Journal of Medicinal Chemistry*, **2010**, 45, 1278-86	6.8	32
21	Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents. *Arzneimittelforschung*, **2009**, 59, 415-21		7
20	A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. *Cancer Prevention Research*, **2009**, 2, 572-80	3.2	68
19	Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. *European Journal of Pharmacology*, **2009**, 602, 8-14	5.3	89
18	Design, synthesis and biological evaluation of novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 5974-82	3.4	66
17	Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. *Molecular Cancer Therapeutics*, **2009**, 8, 3331-40	6.1	82
16	Pharmacokinetics and pharmacodynamics of Phor21-betaCG(ala), a lytic peptide conjugate. *Journal of Pharmacy and Pharmacology*, **2008**, 60, 1441-8	4.8	9
15	First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement. *Journal of Urology*, **2004**, 171, S3-4	2.5	1

14	Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. *Journal of Urology*, **2004**, 171, S59-62; discussion S62-3	2.5	61
13	Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells. *Journal of Experimental Therapeutics and Oncology*, **2003**, 3, 83-94	0.8	11
12	Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. *Molecular Cancer Therapeutics*, **2003**, 2, 479-88	6.1	71
11	Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. *Molecular Cancer Therapeutics*, **2003**, 2, 885-92	6.1	79
10	Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells. *Clinical Cancer Research*, **2003**, 9, 4972-82	12.9	21
9	Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. *Seminars in Oncology*, **2002**, 29, 87-94	5.5	44
8	Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. *Clinical Cancer Research*, **2002**, 8, 904-12	12.9	46
7	Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. *Biochemical Pharmacology*, **1999**, 58, 1097-107	6	158
6	Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. *Urology*, **1999**, 53, 440-5	1.6	108
5	Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. *Breast Cancer Research and Treatment*, **1998**, 48, 195-203	4.4	68
4	Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumor formation by FGN-1 (sulindac sulfone). *Carcinogenesis*, **1998**, 19, 1353-6	4.6	35
3	Lysophosphatidic acid induction of transforming growth factors alpha and beta: modulation of proliferation and differentiation in cultured human keratinocytes and mouse skin. *Experimental Cell Research*, **1995**, 216, 51-64	4.2	82
2	Expression of enzymatically active rat dipeptidyl peptidase IV in Chinese hamster ovary cells after transfection. *Biochemistry*, **1989**, 28, 8474-9	3.2	23
1	Calmodulin and actin polymerization. *Methods in Enzymology*, **1987**, 139, 846-57	1.7	